2026 Guidance Represents Year-Over-Year Increase of 13% in Revenues and 23% in Adjusted EBITDA Based on Mid-Point of 2025 Annual Guidance2026 Annual Guidance is Based Solely on Continued Organic GrowthCompany Continues to Focus on Securing New Business Development and M&A Transactions to Accelerate Long-Term Profitable Growth Kamada Affirms 2025 Guidance of $178 Million - $182 Million in Revenues and $40 Million - $44 Million of Adjusted EBITDA2025 Year-End Cash of Approximately $75 Million REHOVOT, Israel ...

– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 – – Phase 3 DME program first patient dosing expected in Q1 2026 – – Presenting at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 a.m. PT – WATERTOWN, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to develo ...

BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients eligible for 6-month follow-up remaining on treatment for ≥6 months, alongside a potentially differentiated safety profile. Encouraging early efficacy signals were seen in patients with KRASG12C and STK11 and/or KEAP1 co-mutants, where all five initial patients achieved partial response.BBO-8520 in combination wit ...

Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Neil Aubuchon as chief commercial officer. Mr. Aubuchon brings more than two decades of biopharmaceutical industry experience spanning leadership role ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all the outstanding shares of common stock of Cidara Therapeutics, Inc. (Nasdaq: CDTX) ("Cidara†). "The acquisition of Cidara strengthens and complements our expanding respiratory portfolio and exemplifies our business development strategy of investing where compelling science and value meet,†said Robert M. Dav ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the 10 Best US Penny Stocks to Buy. On December 5, Piper Sandler reaffirmed its Buy rating on CytomX Therapeutics, Inc. (NASDAQ:CTMX) with a price target of $6.50. Also on December 5, H.C. Wainwright reiterated its Buy rating on CytomX Therapeutics, Inc. (NASDAQ:CTMX) with a price target of $10. This update comes as the company approaches an important data readout for its CX-2051 therapy in colorectal cancer. H.C. Wainwright outlined specific performance b ...

Geron Corporation (NASDAQ:GERN) is one of the 10 Best US Penny Stocks to Buy. On December 11, H.C. Wainwright maintained its Neutral rating on Geron Corporation (NASDAQ:GERN) after the company announced a strategic restructuring plan. The plan is designed to position the company for long-term value creation while also improving financial discipline. The company shared that its strategic restructuring plan is expected to reduce its workforce by about one-third. When Geron Corporation (NASDAQ:GERN) made th ...

文章核心观点 - 2026年是“十五五”开局之年，A股市场政策向新兴产业倾斜，低估值龙头蓄力，投资机会藏身于国家重点扶持的高景气赛道[1] - 集成电路、新能源、生物医药等被工信部明确为要打造的新兴支柱产业，这些领域的优质标的是未来一年最具潜力的投资方向[1] 筛选逻辑与标准 - 筛选围绕“政策支持+业绩确定性+估值合理”三个核心标准进行[3] - 政策硬支撑：标的属于工信部2026年重点打造的新兴支柱产业，享受研发补贴、产业扶持等政策红利[3] - 业绩有保障：要求2025年营收或净利增速不低于20%，ROE不低于15%，且订单或产能有明确增长预期[3] - 估值不高估：要求PE或PB低于行业均值或处于历史低位，以提供足够安全边际[3] - 所选标的为“政策吹暖风、业绩能兑现、估值不吓人”的优质标的，而非纯概念炒作[4] 重点公司解析 - 北方华创（002371）：作为半导体设备领军者，覆盖刻蚀、沉积等核心环节，国内市占率领先，订单饱满，其PEG仅为1.2[5] - 中国长城（000066）：作为信创硬件核心与PKS体系龙头，2025年股价涨幅仅15%，市盈率约28倍处于历史低位，且资产整合预期强[5] - 德生科技（002908）：属于数据要素与数字经济标的，具备社保服务与数据确权双轮驱动，2026年政策落地加速，呈现小市值高弹性特征[5] 核心赛道投资机会 - 半导体/国产替代：工信部明确推进产业基础再造工程以攻克核心技术，中芯国际、北方华创等公司直接受益于晶圆厂扩产和设备替代[6] - 新能源（光伏+储能）：全国能源工作会议提出2026年新增风电太阳能装机2亿千瓦以上，隆基绿能、宁德时代等公司正处光伏装机和储能需求爆发的风口[6] - 生物医药/创新药：作为新兴支柱产业，在政策趋稳和出海加速背景下，恒瑞医药、华海药业等公司的创新药和CDMO业务有望持续兑现业绩[6] - 以上三个赛道兼具国家战略支持和实际需求增长，被认为是当年A股市场的主线机会[7] 投资方法建议 - 建议投资者查询权威信息，如上交所、深交所官网的公司年报以核实业绩和订单，并使用同花顺等工具查询估值以避开短期暴涨后的高估标的[8] - 建议采取分仓布局策略，不将资金全压于单一赛道，可在半导体、新能源、生物医药中各选1至2只标的以分散风险[8]

UNION, N.J., Jan. 7, 2026 /PRNewswire/ -- Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, today announced an agreement with Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections. The collaboration aims to jointly develop a first-in-class broad-spectrum antifungal for the treatment of severe invasive in ...

Allschwil, Switzerland, January 07, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, today announced an agreement with Prokaryotics Inc., a privately held US-based biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs. The collaboration aims to jointly develop a first-in-class broad-spectrum antifungal for the treatment of sever ...